In the initial in vitro analyses, the Brca-deficient ID8 models were differently sensitized to olaparib-induced toxicity, with the Brca2-deficient tumours demonstrating greater susceptibility to PARP inhibition. This evidence concerns the gene BRCA2 and neoplasm.